Patients receiving B-cell-depleting therapies (BCDT) are at an increased risk for severe COVID-19. Passive antibody therapy (PAT). including COVID-19 convalescent plasma (CCP) and monoclonal antibodies (mAb). may be an effective treatment in this population. https://countryscenesaddleryandpetsuppliers.shop/product-category/endurance-bridle/